Amyloid Plaque Theory

Reducing amyloid burden is described as not producing meaningful improvements in cognition, memory, or daily function. Alzheimer's drug trials focused on amyloid are described as having a 99.6% failure rate. The article argues that amyloid presence in neurodegeneration does not prove amyloid causes the disease. Amyloid plaque is present in people without Alzheimer's, meaning plaque presence does not reliably predict cognitive decline. A 2006 Nature paper linking aβ*56 to cognitive deficits was later found to contain digitally manipulated images and was retracted in 2024. In 2006, a researcher committed scientific fraud by fabricating data that supported the amyloid plaque hypothesis of Alzheimer's disease. The fabricated data misdirected hundreds of millions of research dollars toward the amyloid hypothesis for nearly two decades with almost no productive outcome. The amyloid hypothesis claims that amyloid beta plaques are the causal driver of Alzheimer's disease.